Abstracts tagged "Clinical trials and rheumatoid arthritis"

Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Andreas Kerschbaumer¹, Harald Herkner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting
Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Mark C. Genovese¹, Josephine Glover², Nobuhito Matsunaga³, Diane Chisholm⁴ and Rieke Alten⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, ³Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, ⁴Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, ⁵University Medicine Berlin, Berlin, Germany
Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
Abstract Number: 970 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study
Roy Fleischmann¹, Geraldo Castelar-Pinheiro², Jan Brzezicki³, Pawel Hrycaj⁴, Yong Lin⁵, Janet van Adelsberg⁶, Neil Graham⁷, Hubert van Hoogstraten⁵, Deborah Bauer⁵ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ³Centrum Kliniczno-Badawcze, Elblag, Poland, ⁴Poznan University of Medical Sciences, Poznan, Poland, ⁵Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. The phase 3 MOBILITY study (NCT01061736) evaluated the efficacy and safety…
Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRÃ¡
Iain B. McInnes¹, Gerd Burmester², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, David Close⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, Sara Sandbach¹², Patricia C. Ryan¹³, Dominic Sinibaldi¹⁴, Wendy White¹³, Nadine A. Defranoux¹⁵ and Michael Weinblatt¹⁶, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, ⁷Med Clinic I, University of Cologne, koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹³Translational Sciences, MedImmune, Gaithersburg, MD, ¹⁴R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, ¹⁵Crescendo Bioscience Inc., South San Francisco, CA, ¹⁶Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
Abstract Number: 1793 • 2013 ACR/ARHP Annual Meeting
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Michael Weinblatt¹, Mark C. Genovese², Meilien Ho³, Sally Hollis³, Krystyna Rosiak-Jedrychowicz⁴, Arthur Kavanaugh⁵, David Millson³, Gustavo Leon⁶, Millie Wang³ and Désiréé van der Heijde⁷, ¹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ³AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁴Przychodnia Neuromedyka, Zyrardów, Poland, ⁵University of California, San Diego, La Jolla, CA, ⁶Instituto de Ginecología y Reproducción-Cirugía Mínimamente Invasiva, Surco, Peru, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 52-wk study (NCT01197521) compared Fosta vs placebo (PBO) + methotrexate (MTX) in patients (pts) with active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].